Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Lung-Box device could save more transplant organs

NCT ID NCT02234128

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device called the Toronto EVLP System that keeps donated lungs warm and breathing outside the body. The goal was to see if it is safe to extend the time doctors can preserve and check the lungs before transplant. 118 adults waiting for a lung transplant took part. Researchers compared their outcomes to standard transplant procedures, focusing on survival and lung function after 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Toronto EVLP System (device that keeps donor lungs warm and breathing outside the body)
What this could lead to
If successful, this could allow more donor lungs to be used for transplant by giving doctors more time to assess them safely.
What could go wrong
This is a safety study, not a test of cure. The device may not improve outcomes, and there are standard risks of lung transplant like organ rejection or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

118 people

The number who actually took part.

Started

Jul 2015

Finished

Nov 2019

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Subject Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Male or female patients * All patients, 18 years of age or older * Patient already on or added to the active waiting list for a single or bilateral lung transplant * Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant * Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant Subject Exclusion Criteria: A subject who meets any of the following criteria will be excluded from participation: * Patients listed for same-side lung re-transplantation * Patients listed for multiple organ transplantation including lung and any other organ * Patients listed for live donor lobar transplant * Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia * Patients not initially consented into the study prior to the time of lung transplant * Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS). Donor Lung Inclusion Criteria for EVLP Assessment: The donor lung must meet at least one of the following criteria to proceed with EVLP: * At the time of the clinical evaluation, the donor PaO2/FiO2 \< 300 mmHg * Donor received ≥ 10 units of blood transfusions * Donation after Cardiac Death (DCD) donor * Expected cold ischemic time \> 6 hours * Donor age ≥ 55 years old * Study Center Investigator requires additional assessment ex vivo and/or extended preservation time Donor Lung Exclusion Criteria for EVLP Assessment: The donor lung is excluded from EVLP if at least one of the following criteria have been met: * The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy * Non-persistent purulent secretions that do not clear by hour 3 on EVLP * The donor lung has confirmed evidence of aspiration * The donor lung has significant mechanical lung injury or trauma * The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility \> 10 hours EVLP Lung Inclusion Criteria for Transplantation: The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator: * PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period * and \< 15% increase from baseline value (defined as the first hour collection point) to final value of pulmonary vascular resistance (PVR) * and \< 15% increase from baseline value to final value of peak airway pressure (PawP) * and \< 15% decrease from baseline value to final value of static lung compliance (Cstat) * and the total preservation time (TPT) does not exceed the following: * the initial CIT-1 time from donor to EVLP \> 1 hour and ≤ 10 hours * the EVLP time \> 3 hours and ≤ 6 hours * the second CIT-2 from EVLP cool down to beginning of recipient implantation must be \> 1 hour and ≤ 6 hours for the first lung * the second CIT-2 from EVLP cool down to beginning of recipient implantation must be \> 1 hour and ≤ 10 hours for the second lung * and Study Center Investigator deems lung function suitable for intended subject EVLP Lung Exclusion Criteria for Transplantation: The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met: * PvO2/FiO2 \< 350 mmHg at final EVLP evaluation time period * or ≥ 15% increase from baseline value to final value of pulmonary vascular resistance (PVR) * or ≥ 15% increase from baseline value to final value of peak airway pressure (PawP) * or ≥ 15% decrease from baseline value to final value of static lung compliance (Cstat) * or TPT exceeds any of the following conditions: * CIT-1 \< 1 hour or \> 10 hours * EVLP \< 3 hours or \> 6 hours * CIT-2 \< 1 hour or \> 6 hours for first lung or \> 10 hours for second lung * or Study Center investigator deems lung function unsuitable for intended subject

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Duke University Health System

    Durham, North Carolina, 27705, United States

  • Inova Fairfax Medical Campus

    Falls Church, Virginia, 22042, United States

  • Loyola University Medical Center

    Chicago, Illinois, 60153, United States

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • UPMC

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Maryland Medical Center

    Baltimore, Maryland, 21201, United States

  • University of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.